Found: 94
Select item for more details and to access through your institution.
2121. Isavuconazole (ISAV) as Primary Anti-Fungal Prophylaxis (PAP) in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS): An Open-Label, Prospective Study.
- Published in:
- Open Forum Infectious Diseases, 2019, v. 6, p. S718, doi. 10.1093/ofid/ofz360.1801
- By:
- Publication type:
- Article
Phase II study of azacitidine with pembrolizumab in patients with intermediate‐1 or higher‐risk myelodysplastic syndrome.
- Published in:
- British Journal of Haematology, 2021, v. 195, n. 3, p. 378, doi. 10.1111/bjh.17689
- By:
- Publication type:
- Article
Allogeneic stem cell transplant for patients with myeloproliferative neoplasms in blast phase: improving outcomes in the recent era.
- Published in:
- British Journal of Haematology, 2021, v. 193, n. 5, p. 1004, doi. 10.1111/bjh.17423
- By:
- Publication type:
- Article
Association of gene mutations with time‐to‐first treatment in 384 treatment‐naive chronic lymphocytic leukaemia patients.
- Published in:
- British Journal of Haematology, 2019, v. 187, n. 3, p. 307, doi. 10.1111/bjh.16042
- By:
- Publication type:
- Article
The landscape of genetic mutations in patients with chronic lymphocytic leukaemia and complex karyotype.
- Published in:
- British Journal of Haematology, 2019, v. 187, n. 1, p. e1, doi. 10.1111/bjh.16117
- By:
- Publication type:
- Article
Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments.
- Published in:
- British Journal of Haematology, 2019, v. 185, n. 5, p. 852, doi. 10.1111/bjh.15877
- By:
- Publication type:
- Article
Approach to patients with essential thrombocythaemia and very high platelet counts: what is the evidence for treatment?
- Published in:
- British Journal of Haematology, 2017, v. 176, n. 3, p. 352, doi. 10.1111/bjh.14443
- By:
- Publication type:
- Article
Extraosseous Ewing's sarcoma of the pancreas.
- Published in:
- International Journal of Clinical Oncology, 2012, v. 17, n. 4, p. 399, doi. 10.1007/s10147-011-0311-6
- By:
- Publication type:
- Article
Exploring the landscape of somatic ASXL2 mutations in myeloid neoplasms: Frequency and clinical implications.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 7, p. 1434, doi. 10.1002/ajh.27333
- By:
- Publication type:
- Article
Phase II study of cladribine, idarubicin, and ara‐C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 11, p. 1711, doi. 10.1002/ajh.27054
- By:
- Publication type:
- Article
Low‐dose dasatinib 50 mg/day versus standard‐dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 11, p. 1413, doi. 10.1002/ajh.26689
- By:
- Publication type:
- Article
Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN‐RS‐T) and myelodysplastic syndrome with ring sideroblasts (MDS‐RS).
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 7, p. E246, doi. 10.1002/ajh.26182
- By:
- Publication type:
- Article
Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Novel hematological parameters for the evaluation of patients with myeloproliferative neoplasms: the immature platelet and reticulocyte fractions.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Association of Myelofibrosis Phenotypes with Clinical Manifestations, Molecular Profiles, and Treatments.
- Published in:
- Cancers, 2023, v. 15, n. 13, p. 3331, doi. 10.3390/cancers15133331
- By:
- Publication type:
- Article
Novel Concepts of Treatment for Patients with Myelofibrosis and Related Neoplasms.
- Published in:
- Cancers, 2020, v. 12, n. 10, p. 2891, doi. 10.3390/cancers12102891
- By:
- Publication type:
- Article
Cases in the Management of Polycythemia Vera: A Patient With Progressive Leukocytosis.
- Published in:
- Clinical Advances in Hematology & Oncology, 2022, v. 20, p. 1
- By:
- Publication type:
- Article
Multicolor flow cytometric immunophenotyping is highly sensitive and specific in identifying aberrant mast cells in the diagnostic workup of systemic mastocytosis.
- Published in:
- American Journal of Clinical Pathology, 2024, v. 161, n. 6, p. 598, doi. 10.1093/ajcp/aqad187
- By:
- Publication type:
- Article
Selecting the optimal BTK inhibitor therapy in CLL: rationale and practical considerations.
- Published in:
- Therapeutic Advances in Hematology, 2022, v. 13, p. 1, doi. 10.1177/20406207221116577
- By:
- Publication type:
- Article
Updates in the management of polycythemia vera and essential thrombocythemia.
- Published in:
- Therapeutic Advances in Hematology, 2019, v. 10, p. 1, doi. 10.1177/2040620719870052
- By:
- Publication type:
- Article
Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis.
- Published in:
- European Journal of Haematology, 2018, v. 100, n. 3, p. 257, doi. 10.1111/ejh.13005
- By:
- Publication type:
- Article
It is not always immune thrombocytopenia: a case of MYH9-related platelet disorder caused by a novel mutation.
- Published in:
- European Journal of Haematology, 2013, v. 91, n. 2, p. 191, doi. 10.1111/ejh.12104
- By:
- Publication type:
- Article
AIDS-related plasmablastic lymphoma with dramatic, early response to bortezomib.
- Published in:
- 2009
- By:
- Publication type:
- Letter
New Concepts of Treatment for Patients with Myelofibrosis.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Treatment of Relapsed/Refractory Acute Myeloid Leukemia.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Acute lymphoblastic leukemia secondary to myeloproliferative neoplasms or after lenalidomide exposure.
- Published in:
- Clinical Case Reports, 2018, v. 6, n. 1, p. 155, doi. 10.1002/ccr3.1264
- By:
- Publication type:
- Article
Remission of rheumatoid arthritis on brentuximab vedotin.
- Published in:
- 2014
- By:
- Publication type:
- Journal Article
Remission of rheumatoid arthritis on brentuximab vedotin.
- Published in:
- 2014
- By:
- Publication type:
- Letter to the Editor
SOHO State of the Art Updates and Next Questions | Diagnosis, Outcomes, and Management of Prefibrotic Myelofibrosis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2024, v. 24, n. 7, p. 413, doi. 10.1016/j.clml.2024.01.009
- By:
- Publication type:
- Article
SOHO State of the Art Updates and Next Questions: Novel Therapies in Development for Myelofibrosis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 4, p. 210, doi. 10.1016/j.clml.2021.10.002
- By:
- Publication type:
- Article
SOHO State of the Art Updates and Next Questions: Identifying and Treating "Progression" in Myelofibrosis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, n. 10, p. 641, doi. 10.1016/j.clml.2021.06.008
- By:
- Publication type:
- Article
MPN-332: Clinical Benefit of Pelabresib (Cpi-0610) in Combination with Ruxolitinib in JAK Inhibitor Treatment-Naïve Myelofibrosis Patients: Interim Efficacy Subgroup Analysis from Arm 3 of the MANIFEST Phase 2 Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S362, doi. 10.1016/S2152-2650(21)01833-4
- By:
- Publication type:
- Article
MPN-328: Pelabresib (CPI-0610) Improved Anemia Associated with Myelofibrosis: Interim Results from the Ongoing MANIFEST Phase 2 Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S361, doi. 10.1016/S2152-2650(21)01832-2
- By:
- Publication type:
- Article
MPN-314: Improved Survival of Patients with Primary Myelofibrosis in the Last Decade at a Large Single Academic Center.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S361, doi. 10.1016/S2152-2650(21)01831-0
- By:
- Publication type:
- Article
CLL-348: STAT3 Induces the Expression of GLI1 in Chronic Lymphocytic Leukemia Cells.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S322, doi. 10.1016/S2152-2650(21)01759-6
- By:
- Publication type:
- Article
Poster: MPN-328: Pelabresib (CPI-0610) Improved Anemia Associated with Myelofibrosis: Interim Results from the Ongoing MANIFEST Phase 2 Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S234, doi. 10.1016/S2152-2650(21)01476-2
- By:
- Publication type:
- Article
Poster: MPN-332: Clinical Benefit of Pelabresib (Cpi-0610) in Combination with Ruxolitinib in JAK Inhibitor Treatment-Naïve Myelofibrosis Patients: Interim Efficacy Subgroup Analysis from Arm 3 of the MANIFEST Phase 2 Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S234, doi. 10.1016/S2152-2650(21)01477-4
- By:
- Publication type:
- Article
Poster: MPN-314: Improved Survival of Patients with Primary Myelofibrosis in the Last Decade at a Large Single Academic Center.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S232, doi. 10.1016/S2152-2650(21)01458-0
- By:
- Publication type:
- Article
Poster: CLL-348: STAT3 Induces the Expression of GLI1 in Chronic Lymphocytic Leukemia Cells.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S222, doi. 10.1016/S2152-2650(21)01401-4
- By:
- Publication type:
- Article
Clinical Significance of Bone Marrow Blast Percentage in Patients With Myelofibrosis and the Effect of Ruxolitinib Therapy.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, n. 5, p. 318, doi. 10.1016/j.clml.2020.12.024
- By:
- Publication type:
- Article
A Young Woman with Thrombocytosis.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Identifying and Treating "Progression" in Myelofibrosis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S36, doi. 10.1016/j.clml.2019.07.411
- By:
- Publication type:
- Article
The Early Achievement of Measurable Residual Disease Negativity in the Treatment of Adults with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia is a Strong Predictor for Survival.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S193, doi. 10.1016/j.clml.2019.07.040
- By:
- Publication type:
- Article
Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia.
- Published in:
- 2019
- By:
- Publication type:
- journal article
The Landscape of Genetic Mutations in Patients with Chronic Lymphocytic Leukemia and Complex Karyotype.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S212, doi. 10.1016/j.clml.2018.07.074
- By:
- Publication type:
- Article
MEK Inhibitor Binimetinib (MEK162) in Relapse and Refractory Acute Myeloid Leukemia: Results of a Phase I/II Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S199, doi. 10.1016/j.clml.2018.07.046
- By:
- Publication type:
- Article
Extended Abstract: Accelerated Phase Myelofibrosis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S40, doi. 10.1016/j.clml.2018.06.050
- By:
- Publication type:
- Article
A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma.
- Published in:
- 2018
- By:
- Publication type:
- journal article
SOHO State-of-the-Art Update and Next Questions: MPN.
- Published in:
- 2018
- By:
- Publication type:
- journal article